American Society of Gene & Cell Therapy

THANK YOU to everyone who joined our inaugural Empowering Patients 2025 Summit! Groundbreaking conversations between FDA leaders, patient advocates, and researchers illuminated the transformative potential of cell and gene therapies. 👏 Missed it? You can still register FREE for on-demand access to all sessions. Plus, mark your calendars - all content will be available on our YouTube channel (youtube.com/@ASGCT) on April 11! Register now to equip yourself with the knowledge that empowers informed decisions—from understanding the science to navigating clinical trials—and join the community driving access to life-changing therapies. Registration: www.asgct.org/ep2025

📢 Happening TOMORROW, March 18: Register for a free webinar from Cell Press and #MolecularTherapy Oncology (#MTO)!   During Applications of Single-cell RNA Sequencing in Cancer, our speakers will discuss different applications of this powerful technology in cancer biology and therapeutics. Join us tomorrow at noon (ET): https://lnkd.in/gFg-TXAz

We appreciated meeting with Nanette Barragán's office on how NIH F&A/indirect funding advances #celltherapies and #genetherapies. Your support for research helps drive innovation and ensures life-saving treatments reach patients. #ASGCTadvocacy 

Fireside Chats at #ASGCT2025: Expert Discussions on the Future of CGT Join thought-provoking conversations about the future of cell and gene therapy at our Fireside Chats, where leading experts gather to discuss the field's most significant challenges and opportunities. ✨ Why attend? - Hear directly from global regulators on harmonizing worldwide frameworks (Wed, May 14, 8 am) - Explore strategies and considerations for revisiting deprioritized therapy programs (Wed, May 14, 3:45 pm) - Learn about innovative funding models from NIH, ARPA-H and venture capital leaders (Thu, May 15, 8 am) These sessions offer an interactive format that encourages open dialogue and practical insights on important questions facing the CGT field. Whether you're in industry, academia, patient advocacy, or regulation, these discussions provide valuable perspectives. Join us in New Orleans May 13-17 for the most comprehensive cell and gene therapy event of the year! www.asgct.org/2025 #CellAndGeneTherapy #CGT2025 #ASGCT #CGT

🎤 This week on The Issue with Emily Walsh Martin, PhD: The When, What, How, and Why of FDA Engagement with Nicole (Niki) Gallo, RAC Whether you’re from industry or academia, this conversation will help wrap all our heads around testing novel therapies for the first time in humans. Listen to the episode + subscribe to the ASGCT Podcast Network! https://lnkd.in/gX2YVnUQ

Thank you to Sen. John Fetterman’s office for taking the time to meet with ASGCT leadership on Capitol Hill. #CGT research brings life-changing treatments to patients who need them most – it was great to discuss the federal policies and funding that support the pipeline. https://lnkd.in/gR3z_HAK #ASGCTadvocacy  

Coming up 🔜: Single-cell RNA sequencing (scRNAseq) is a powerful tool used for characterizing the individual transcriptional landscape of thousands of individual cells simultaneously. Insights gained from scRNAseq help us better understand tumor biology, find therapeutic vulnerabilities, and identify prognostic biomarkers.   On March 18, learn more about the applications for this technology in cancer biology and therapeutics during a free webinar from Cell Press in partnership with our journal #MolecularTherapy Oncology (#MTO). Register for FREE: https://lnkd.in/gFg-TXAz

ASGCT leadership met with Sen. Katie Britt's office last week on Capitol Hill to dive into NIH research funding and its impact on American competitiveness in biomedical development. Thanks for a great conversation! #ASGCTadvocacy 

During the #EmpoweringPatients session on CGT Manufacturing Basics, we explored key differences in genetic medicine production: 🧬 ASO Therapies – are small but precise, about 15–30 nucleotides  🦠 AAV #GeneTherapy – 4,700 nucleotides in viral particles  🧑🔬 𝙚𝙭 𝙫𝙞𝙫𝙤 Gene Therapy – 6 million nucleotides in whole human cells Manufacturing complexity increases with size and delivery method—highlighting why each therapy is uniquely developed. Although there is great desire to make these processes more bespoke, this helps us understand why CGT development takes time and comes at a higher cost.  Check out the full session, available on-demand for 30 days to registered attendees: https://lnkd.in/gNchxqcG Thank you to all who attended and engaged!

LIVE NOW! Grab your coffee and join 𝗗𝗿. 𝗣𝗲𝘁𝗲𝗿 𝗠𝗮𝗿𝗸𝘀 for an exclusive Morning Coffee Chat at the Empowering Patients Summit!  Get insights on:  ✅ Patient-focused drug development  ✅ How the FDA is amplifying the patient voice in drug review  ✅ Accelerated approval and other expedited programs  Register: https://lnkd.in/gcqCkBTK  #ASGCTAdvocacy #EmpoweringPatients